European Commission (EC) grants marketing authorization for AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and olderAGAMREE® is the only approved medication in the European Union (EU) for treating DMD, and the first DMD treatment approved in both the U.S. and EUFirst commercial launch of AGAMREE®, in Germany, expected in Q1-2024 EMA acknowledges safety benefits of AGAMREE® with regards to preserving bone health and maintaining growth compared to standard
Santhera Pharmaceuticals Holding AG: Santhera's AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
18.12.2023 - European Commission (EC) grants marketing authorization for AGAMREE for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and olderAGAMREE is the only approved medication in the European Union (EU) for treating DMD, and the . Seite 1
DelveInsight Business Research, LLP: In-Depth Market Analysis of Rare Genetic Disorders: Familial Chylomicronemia Syndrome (FCS), Netherton Syndrome, and Acromegaly finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.